Pacira BioSciences (PCRX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.73
- EPS estimate
- $0.65
- EPS surprise
- +12.95%
- Revenue surprise
- +0.70%
- Revenue
- $192.4M
- Revenue estimate
- $191.1M
- Reported
- Aug 4, 2026
Pacira reported Q2 2026 results on August 4, 2026. Earnings per share came in at $0.73, beating the $0.65 estimate by 12.95%. Revenue was $192.4 million, just above the $191.1 million consensus. Compared with Q2 2025, EPS was about 1% lower than $0.74, while revenue rose about 6% from $181.1 million.
Annual revenue rose from $666.9 million in 2022 to $726.4 million in 2025, and Q4 2025's $196.9 million is the highest quarter in the table. Earnings have been less even. Annual EPS went from $2.59 in 2022 to $2.92 in 2023 and $3.21 in 2024, then fell about 18% to $2.63 in 2025. The first half of 2026 adds up to $1.33, close to $1.36 a year earlier. Every quarter shown was profitable. Over the last 20 quarters, Pacira beat the EPS estimate 12 times. Its largest miss was Q2 2022, at 40.15%, and the latest was Q4 2025, at 37.01%.
Pacira reported Q3 results between November 2 and November 6 in each of the past five years. That points to early November 2026 for the next report. It will show whether revenue growth continues and whether EPS moves back above year-earlier levels.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | $0.65 | $0.73 | +12.95% | $192.4M | SEC |
| Q1 2026 | Apr 30, 2026 | $0.55 | $0.60 | +9.57% | $177.4M | SEC |
| Q4 2025 | Feb 26, 2026 | $0.90 | $0.57 | −37.01% | $196.9M | SEC |
| Q3 2025 | Nov 6, 2025 | $0.68 | $0.70 | +3.32% | $179.5M | SEC |
| Q2 2025 | Aug 5, 2025 | $0.71 | $0.74 | +4.23% | $181.1M | SEC |
| Q1 2025 | May 8, 2025 | $0.60 | $0.62 | +3.94% | $168.9M | SEC |
| Q4 2024 | Feb 27, 2025 | $0.84 | $0.91 | +8.94% | $187.3M | SEC |
| Q3 2024 | Nov 6, 2024 | $0.70 | $0.79 | +12.14% | $168.6M | SEC |
| Q2 2024 | Jul 30, 2024 | $0.70 | $0.89 | +27.34% | $178.0M | SEC |
| Q1 2024 | May 7, 2024 | $0.62 | $0.62 | −0.02% | $167.1M | SEC |
| Q4 2023 | Feb 29, 2024 | $0.88 | $0.89 | +0.76% | $181.2M | SEC |
| Q3 2023 | Nov 2, 2023 | $0.78 | $0.72 | −7.78% | $163.9M | SEC |
| Q2 2023 | Aug 2, 2023 | $0.76 | $0.78 | +2.81% | $169.5M | SEC |
| Q1 2023 | May 3, 2023 | $0.62 | $0.53 | −14.10% | $160.3M | SEC |
| Q4 2022 | Feb 28, 2023 | $0.83 | $0.80 | −3.56% | $172.0M | SEC |
| Q3 2022 | Nov 3, 2022 | $0.77 | $0.64 | −16.51% | $167.5M | SEC |
| Q2 2022 | Aug 3, 2022 | $0.85 | $0.51 | −40.15% | $169.4M | SEC |
| Q1 2022 | May 4, 2022 | $0.83 | $0.64 | −23.06% | $158.0M | SEC |
| Q4 2021 | Feb 24, 2022 | $0.90 | $0.97 | +7.42% | $159.2M | SEC |
| Q3 2021 | Nov 3, 2021 | $0.65 | $0.72 | +10.77% | $127.7M | SEC |
Quarterly revenue
Frequently asked questions
When did Pacira BioSciences (PCRX) last report earnings?
Pacira BioSciences last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did PCRX beat earnings estimates?
Yes. Pacira BioSciences reported EPS of $0.73 for Q2 2026 against a $0.65 estimate — a 12.95% beat.
How much revenue did PCRX report last quarter?
Pacira BioSciences reported $192.4M in revenue for Q2 2026, against a consensus estimate of $191.1M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.